Changes in Thyroid Functional Tests in Breast Cancer Patients under Tamoxifen Therapy

AUTHORS

HR Mirzaei 1 , Afshin Rakhsha 2 , * , A Fazlallizadeh 3 , B Mofid 1 , M Hoshiari 2

1 Cancer Research Centre, Shahid Beheshti University (MC); Radiation Oncology, Shahid Beheshti University (MC) shohada Hospital, Iran

2 Radiation Oncology, Shahid Beheshti University (MC) shohada Hospital, Iran

3 Radiation Oncology, Shahid Beheshti University (MC), Imam Hossein Hospital, Iran

How to Cite: Mirzaei H, Rakhsha A , Fazlallizadeh A, Mofid B, Hoshiari M. Changes in Thyroid Functional Tests in Breast Cancer Patients under Tamoxifen Therapy , Int J Cancer Manag. 2008 ; 1(3):e80446.

ARTICLE INFORMATION

International Journal of Cancer Management: 1 (3); e80446
Published Online: September 30, 2008
Article Type: Research Article
Received: September 30, 2008
Accepted: September 30, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Tamoxifen, a synthetic anti-estrogen agent, is administered as an adjuvant treatment in breast cancer. Since various studies have indicated that Tamoxifen can change some hormones and bound globolines, controversial results have been achieved using this medicine on Thyroid Functional Tests (TFT). The present study was conducted to investigate the effects of Tamoxifen on TFT in women with breast cancer referred to oncology clinic in Imam Hossein hospital between 2001 and 2002.

Method: A quasi-experimental clinical trial study was performed on 23 women with breast cancer in a single blind basis (with no control group). Patients were under Tamoxifen 20 mg P.O. daily and their serum TSH, free T4 and three Iodothyronine (T3) were assessed before treatment with Tamoxifen and after 3 months. Paired T test was used for statistical analysis.

Results: There was a significant difference in T3 before and after the treatment with Tamoxifen (p=0.02), whereas no significant differences were seen in TSH (p=0.095) and FT4 (p=0.13).

Discussion: This study showed that treatment with Tamoxifen in women suffering from breast cancer results in an increase in serum T3 but has no effect on serum TSH and FT4, therefore women under treatment with Tamoxifen remain euthyroid.

Keywords

thyroid function tests breast cancer tamoxifen

© 2008, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

Full text is available in PDF.
 

COMMENTS

LEAVE A COMMENT HERE: